Compare Kinross Gold Corporation (KGC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs TransMedics Group Inc — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Kinross Gold Corporation is far larger — about 10.1× TransMedics Group Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and TransMedics Group Inc for 24 Days on average.
| KGC | TMDX | |
|---|---|---|
Market Cap | $27.62B | $2.74B |
Volume | 6,347,266 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $150.42 |
52-Week Low | $22.47 | $61.99 |
Typical Hold Time | 53 Days | 24 Days |
Enterprise Value | $25.70B | $3.13B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold Corporation (KGC) trades at $23.34, up 0.69% today, with strong fundamentals including a P/E of 8.87 and robust profitability metrics. Recent earnings have consistently beaten expectations, though technical indicators signal bearish momentum. The company reported $7.05B revenue and $2.39B net income for 2025, with cash flow from operations reaching $3.76B. However, production guidance cuts for 2026-2027 have pressured the stock, offset by increased shareholder returns targeting 50% of free cash flow.
KGC presents a mixed outlook: attractive valuation and earnings growth support upside to the $38.80 consensus price target, but near-term risks include operational setbacks at key mines and ongoing legal investigations. The stock's bearish technical trend and rising costs warrant caution, though institutional buying and high analyst buy ratings (58.63%) indicate underlying confidence in long-term value.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
